Literature DB >> 17523771

Melaena following Use of the Cholinesterase Inhibitor Rivastigmine.

Pietro Gareri1, Luca Gallelli, Guido Ferreri Ibbadu, Roberto Lacava, Emilio Russo, Giovambattista De Sarro.   

Abstract

Entities:  

Year:  2005        PMID： 17523771     DOI： 10.2165/00044011-200525030-00008

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  13 in total

Review 1.  Cell biology of acid secretion by the parietal cell.

Authors:  Xuebiao Yao; John G Forte
Journal:  Annu Rev Physiol       Date:  2002-08-05       Impact factor: 19.318

Review 2.  Omeprazole: the first proton pump inhibitor.

Authors:  P Lindberg; A Brändström; B Wallmark; H Mattsson; L Rikner; K J Hoffmann
Journal:  Med Res Rev       Date:  1990 Jan-Mar       Impact factor: 12.944

Review 3.  Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

Authors:  R J Polinsky
Journal:  Clin Ther       Date:  1998 Jul-Aug       Impact factor: 3.393

4.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 5.  Gastroprotective agents for the prevention of NSAID-induced gastropathy.

Authors:  J J Ares; P E Outt
Journal:  Curr Pharm Des       Date:  1998-02       Impact factor: 3.116

Review 6.  Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders.

Authors:  A Desai; G Grossberg
Journal:  Expert Opin Pharmacother       Date:  2001-04       Impact factor: 3.889

7.  Rivastigmine in outpatient services: experience of 114 neurologists in Austria.

Authors:  R Schmidt; A Lechner; K Petrovic
Journal:  Int Clin Psychopharmacol       Date:  2002-03       Impact factor: 1.659

8.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Authors:  M Rösler; R Anand; A Cicin-Sain; S Gauthier; Y Agid; P Dal-Bianco; H B Stähelin; R Hartman; M Gharabawi
Journal:  BMJ       Date:  1999-03-06

9.  [Tolerance and adverse events of treatment with acetylcholinesterase inhibitors in a clinical sample of patients with very slight and mild Alzheimer s disease over a six-month period].

Authors:  A Turon-Estrada; S López-Pousa; E Gelada-Batlle; J Garre-Olmo; M Lozano-Gallego; M Hernández-Ferràndiz; C Fajardo-Tibau; V Morante-Muñoz; J Vilalta-Franch
Journal:  Rev Neurol       Date:  2003 Mar 1-15       Impact factor: 0.870

Review 10.  The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.

Authors:  F Inglis
Journal:  Int J Clin Pract Suppl       Date:  2002-06
View more
  6 in total

1.  Acetylcholine Inhibits Platelet Activation.

Authors:  John A Bennett; Sara K Ture; Rachel A Schmidt; Michael A Mastrangelo; Scott J Cameron; Lara E Terry; David I Yule; Craig N Morrell; Charles J Lowenstein
Journal:  J Pharmacol Exp Ther       Date:  2019-02-14       Impact factor: 4.030

2.  The CITIRIVAD Study: CITIcoline plus RIVAstigmine in Elderly Patients Affected with Dementia Study.

Authors:  Alberto Castagna; Antonino Maria Cotroneo; Giovanni Ruotolo; Pietro Gareri
Journal:  Clin Drug Investig       Date:  2016-12       Impact factor: 2.859

3.  Effects of phenobarbital and levetiracetam on PR and QTc intervals in patients with post-stroke seizure.

Authors:  Antonio Siniscalchi; Francesco Scaglione; Enzo Sanzaro; Francesco Iemolo; Giorgio Albertini; Gianluca Quirino; Maria Teresa Manes; Santo Gratteri; Nicola Biagio Mercuri; Giovambattista De Sarro; Luca Gallelli
Journal:  Clin Drug Investig       Date:  2014-12       Impact factor: 2.859

4.  Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis.

Authors:  Marinella Patanè; Miriam Ciriaco; Serafina Chimirri; Francesco Ursini; Saverio Naty; Rosa Daniela Grembiale; Luca Gallelli; Giovambattista De Sarro; Emilio Russo
Journal:  Adv Pharmacol Sci       Date:  2013-05-12

5.  Somatic comorbidities and Alzheimer's disease treatment.

Authors:  Alessandra Clodomiro; Pietro Gareri; Gianfranco Puccio; Francesca Frangipane; Roberto Lacava; Alberto Castagna; Valeria Graziella Laura Manfredi; Rosanna Colao; Amalia Cecilia Bruni
Journal:  Neurol Sci       Date:  2013-02-01       Impact factor: 3.307

6.  Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis.

Authors:  Raffaele Serra; Raffaele Grande; Gianluca Buffone; Edoardo Scarcello; Fabio Tripodi; Pierandrea Rende; Luca Gallelli; Stefano de Franciscis
Journal:  J Pharmacol Pharmacother       Date:  2014-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.